OR WAIT null SECS
Surveying Pharma Workers on Employment Trends
Appreciating the full impact certain select technologies will make on the industry by 2026.
Pharma workers appear ready for flux, change, evolution, and expanding molecular diversity.
Experts weigh in on trends in the biotechnology market, psychedelics, and India.
Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.
Analytical techniques for cleaning validation must evolve with the therapeutic landscape.
Pharma Trends Dissected by 3 PR Agency Luminaries
January 26, 2023
Agilent will work with Quest Diagnostics to distribute the ctDx FIRST test.
deCODE genetics, a subsidiary of Amgen, will whole-genome sequence 35,000 African-American samples provided by Illumina and Nashville Biosciences.
The United States Patent and Trademark Office issued a Notice of Allowance for Zika vaccine patent to GeoVax.
January 24, 2023
Jill Murphy, editor, and Grant Playter, associate editor, discuss the results from Pharmaceutical Technology’s latest employment survey.
January 23, 2023
Takeda will pay approximately $400 million upfront for the exclusive worldwide rights to Hutchmed’s fruquintinib, a tyrosine kinase inhibitor, outside of China.
In a response letter, FDA stated that it could not grant Eli Lilly and Company accelerated approval due to concerns surrounding insufficient quantity of clinical trial data.
The guidance is intended to provide nonclinical, virology, and clinical considerations for mpox drug development programs, targeting on recommendations to support initiation of clinical trials.
January 20, 2023
The efficacy data across multiple clinical endpoints and a favorable safety profile support the potential of AMB-05X as a best-in-class therapy for the treatment of TGCT regardless of surgical resectability.
The partnership led to Asimov licensing its clonal GMP HEK293 suspension cell line to CBM for pre-clinical and clinical production of viral vectors for its clients.
CRB’s latest industry report includes an expanded audience to include many European countries, which has provided some interesting insights.